Categories Analysis, Consumer

What to expect when Tyson Foods (TSN) reports Q3 2023 earnings results

Analysts are projecting revenue of $13.6 billion for Q3 2023

Shares of Tyson Foods, Inc. (NYSE: TSN) were up 1% on Friday. The stock has dropped 8% year-to-date. The company is slated to report its third quarter 2023 earnings results on Monday, August 7, before market open. Here’s a look at what to expect from the earnings report:

Revenue

Analysts are projecting revenue of $13.6 billion for Q3 2023, which is up slightly from sales of $13.5 billion in the same period a year ago. In the second quarter of 2023, sales remained flat year-over-year at $13.1 billion.

Earnings

The consensus estimate for EPS is $0.26 in Q3 2023, which compares to EPS of $1.94 in the year-ago quarter. In Q2 2023, the company reported an adjusted loss of $0.04 per share.

Points to note

Tyson expects global demand for protein to continue to grow which is a positive. It plans to focus on driving growth in its core protein platform and remains well-positioned with the capacity to meet the protein demand.

The company could benefit from growth in its branded food portfolio aided by strength in brands such as Tyson, Jimmy Dean and Hillshire Farm. In Q2, branded foods saw volume growth of 7%. Branded foods presents meaningful opportunity to drive growth and improve margins.

In Q2, Tyson saw sales growth in chicken and prepared foods. Sales in chicken increased over 8% helped by volume growth of over 6% due to increased internal production. Sales also benefited from pricing actions. Sales in prepared foods rose 1.2% driven mainly by pricing gains.

Higher input costs are a concern. In Q2, higher input costs per pound in all segments, barring pork, led to an increase in cost of goods sold. Most of this increase was driven by the impacts of inflation on raw material and labor costs.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top